300 North Capital’s Celldex Therapeutics CLDX Stock Holding History

300 North Capital’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-4,417	Closed	-$1.85M	–	53
2015 Q1	$1.85M	Buy	4,417 +49	+1%	+$17.5K	0.41%	89
2014 Q4	$1.2M	Buy	4,368 +1,633	+60%	+$406K	0.28%	88
2014 Q3	$533K	Hold	2,735	–	–	0.14%	96
2014 Q2	$670K	Hold	2,735	–	–	0.17%	85
2014 Q1	$725K	Buy	2,735 +146	+6%	+$55.9K	0.19%	85
2013 Q4	$940K	Sell	2,589 -200	-7%	-$77K	0.26%	80
2013 Q3	$1.48M	Buy	+2,789	New	+$956K	0.35%	93

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

300 North Capital's CLDX Position: Q2 2015 in Review

300 North Capital sold out of Celldex Therapeutics (CLDX) in Q2 2015, closing a stake of 4,417 shares — an estimated $1.85M sold.

300 North Capital first reported a position in CLDX in Q3 2013 and held it in 7 quarters. The position peaked at $1.85M in Q1 2015. 186 funds tracked by Wall St. Rank hold CLDX as of Q2 2015.

300 North Capital reported no remaining Celldex Therapeutics position as of Q2 2015 after selling out during the quarter.
300 North Capital sold 4,417 Celldex Therapeutics shares in Q2 2015, an estimated $1.85M.
300 North Capital first reported a position in Celldex Therapeutics in Q3 2013 and held it in 7 quarters.
300 North Capital's Celldex Therapeutics position peaked at $1.85M in Q1 2015.
186 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2015.

Based on 300 North Capital's 13F filing for Q2 2015, filed 30 Jul 2015.